Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy

References

• KesslerRCBerglundPDemlerOThe epidemiology of major depressive disorder. Results from the National Comorbidity Survey Replication (NCS-R)JAMA20032893095310512813115
   PubMed Web of Science ®Google Scholar
• MurrayCJLopezADEvidence-based health policy – lessons from the Global Burden of Disease StudyScience19962747407438966556
   PubMed Web of Science ®Google Scholar
• GreenbergPEKesslerRCBirnbaumHGThe economic burden of depression in the United States: how did it change between 1990 and 2000?J Clin Psychiatry2003641465147514728109
   PubMed Web of Science ®Google Scholar
• IvanovaJIBirnbaumHGKidoleziYSubramanianGKhanSAStenslandMDDirect and indirect costs of employees with treatment-resistant and non-treatment resistant major depressive disorderCurr Med Res Opin2010262475248420825269
   PubMed Web of Science ®Google Scholar
• RushAJTrivediMHWisniewskiSRAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportAm J Psychiatry20061631905191717074942
   PubMed Web of Science ®Google Scholar
• ConnollyKRThaseMEIf at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination, and switching strategiesDrugs201171436421175239
   PubMed Web of Science ®Google Scholar
• FavaMDiagnosis and definition of treatment-resistant depressionBiol Psychiatry20035364965912706951
   PubMed Web of Science ®Google Scholar
• CrownWHFinkelsteinSBerndtERThe impact of treatment-resistant depression on health care utilization and costsJ Clin Psychiatry20026396397112444808
   PubMed Web of Science ®Google Scholar
• GreenbergPCorey-LislePKBirnbaumHMarynchenkoMClaxtonAEconomic implications of treatment-resistant depression among employeesPharmacoeconomics20042236337315099122
   PubMed Web of Science ®Google Scholar
• Corey-LislePKBirnbaumHGGreenbergPEMarynchenkoMBClaxtonAJIdentification of a claims data “signature” and economic consequences for treatment-resistant depressionJ Clin Psychiatry20026371772612197453
   PubMed Web of Science ®Google Scholar
• RussellJMHawkinaKOzminkowskiRHThe cost consequences of treatment-resistant depressionJ Clin Psychiatry20046534134715096073
   PubMed Web of Science ®Google Scholar
• GibsonTBJingYSmith CarlsGCost burden of treatment resistance in patients with depressionAm J Manag Care20101637037720469957
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationPractice Guideline for the Treatment of Patients with Major Depressive Disorder3rd edArlingtonAmerican Psychiatric Publishing2010
   Google Scholar
• NemeroffCBUse of atypical antipsychotics in refractory depression and anxietyJ Clin Psychiatry200566Suppl 8132116336032
   PubMed Web of Science ®Google Scholar
• PapakostasGESheltonRCUse of atypical antipsychotics for treatment-resistant major depressive disorderCurr Psychiatry Rep20081048148618980731
   PubMedGoogle Scholar
• JingYKalsekarICurkendallSMIntent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depressionClin Ther2011331246125721840058
   PubMed Web of Science ®Google Scholar
• IMS HealthIMS RxBenchmark: PharMetrics Integrated Database Available from: http://www.imshealth.com/portal/site/ims/menuitem.d248e29c86589c9c30e81c033208c22a/?vgnextoid=d6952a2e23264310VgnVCM100000ed152ca2RCRD&vgnextchannel=c03c90916e442310VgnVCM100000ed152ca2RCRDAccessed September 20, 2012
   Google Scholar
• DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol1992456136191607900
   PubMed Web of Science ®Google Scholar
• AshcraftMLFriesBENerenzDRA psychiatric patient classification system. An alternative to diagnosis-related groupsMed Care1989275435572498585
   PubMed Web of Science ®Google Scholar
• PetersenTPapakostasGEPosternakMAEmpirical testing of two models for staging antidepressant treatment resistanceJ Clin Psychopharmacol20052533634116012276
   PubMed Web of Science ®Google Scholar
• Bristol-Myers SquibbAbilify (aripiprazole) [package insert]PrincetonBristol-Myers Squibb2011
   Google Scholar
• Eli LillyZyprexa (olanzapine) [package insert]IndianapolisEli Lilly2011
   Google Scholar
• AstraZenecaSeroquel (quetiapine) [package insert]WilmingtonAstraZeneca2011
   Google Scholar
• TanejaCPapakostasGIJingYBakerRAForbesRAOsterGCost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorderAnn Pharmacother20124664264922550279
   PubMed Web of Science ®Google Scholar
• LeslieDLMohamedSRosenheckRAOff-label use of antipsychotic medications in the Department of Veterans Affairs health care systemPsychiatr Serv2009601175118119723731
   PubMed Web of Science ®Google Scholar
• BroderMSBatesJAJingYHebdenTForbesRAChangEAssociation between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophreniaJ Med Econ20121510511121991926
   PubMedGoogle Scholar